Log In
No results found for "".

Deal Details

C/PIndustryStatusTicker(s)Issuer(s)Size(m)TranchesRegionDate
IGC
HLTH
PRCD
TEVA
Teva Pharmaceutical Finance Netherlands II BV€1,500
2EMEA
Sep 9, 2026
currency
EUR
size (m)
1,000.000
maturity
Mar 16, 2033
type
Fixed
tenor
6.500
call
-
registration
SEC Registered
benchmark
Swaps
ranking
Sr. Unsecured
moody's
Baa3
s&p
BBB-
fitch
BBB-
size description
-
re-open/tap
No
ipt
MS+145 area
ipt-pxd
-35
guidance
STL
spread
110
coupon
4.25%
spread set
-
price
98.75600
yield
4.479%
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
billing & delivering
active leads
joint leads
-
passive leads
co-managers
coordinating managers
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
billing & delivering
active leads
joint leads
-
passive leads
co-managers
coordinating managers
currency
EUR
size (m)
500.000
maturity
Sep 16, 2036
type
Fixed
tenor
10.000
call
-
registration
SEC Registered
benchmark
Swaps
ranking
Sr. Unsecured
moody's
Baa3
s&p
BBB-
fitch
BBB-
size description
-
re-open/tap
No
ipt
MS+175 area
ipt-pxd
-37.5
guidance
STL
spread
137.5
coupon
4.625%
spread set
-
price
98.32700
yield
4.84%
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
billing & delivering
active leads
joint leads
-
passive leads
co-managers
coordinating managers
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
billing & delivering
active leads
joint leads
-
passive leads
co-managers
coordinating managers
Tranche Comments
Registration: SEC Registered; Comments: DBR 2.3% Feb-33 TWIN @ 94.49 / 3.262% / B+121.7bp (HR: 100%). MWC: B+20. CoC: 101%. DBR 2.3% 02/33 TWIN @ 94.49 / 3.262% / b+121.7bps (HR: 100%); Registration: SEC Registered; Comments: DBR 3% Aug-36 @ 96.35 / 3.439% / B+140.1bp (HR: 96%). MWC: B+25. CoC: 101%. DBR 3% 08/36 @ 96.35 / 3.439% / b+140.1bps (HR: 96%);
Guarantor(s)
Teva Pharmaceutical Industries Ltd
Use of Proceeds
Teva intends to use the net proceeds of this offering, together with cash on hand, (i) to fund the Conditional Redemptions (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, for general corporate purposes, including the repayment of outstanding debt upon maturity, tender offer or earlier redemption